CARB-X partners with accelerators around the world to provide scientific, technical and business support to CARB-X-funded product developers. The Network is a one-of-a-kind source of knowhow and expertise in antibacterial drug development, diagnostics, business strategy and other areas essential to supporting CARB-X’s growing portfolio of early development research projects.
CARB-X Global Accelerators
California Life Sciences Institute (CLSI): CLSI provides a range of business support to CARB-X companies. Located in one of the world’s most innovative and productive biotech hubs, South San Francisco, California, USA, this accelerator has extensive experience nurturing start-ups towards Series A financing and beyond. Since start-ups often fail for business reasons unrelated to science, CLSI specializes in business support and mentoring services to innovative product developers.
Centre for Cellular and Molecular Platforms (C-CAMP): C-CAMP is India’s premier Life Science innovation, entrepreneurship and technology hub as well as one of the largest life science incubators in the country. C-CAMP provides, funding, incubation, acceleration and mentorship to start-ups, and has built a vibrant ecosystem to nurture deep science driven enterprises. An initiative of the Indian Government’s Department of Biotechnology, Ministry of Science and Technology and located in Bangalore, C-CAMP has funded, incubated and mentored over 110 start-ups in recent years.
Foundation for Innovative New Diagnostics (FIND): FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. Its work bridges R&D to access, overcoming scientific barriers to technology development; generating evidence for regulators and policy-makers; addressing market failures; and enabling accelerated uptake and access to diagnostics in low- and middle-income countries. A WHO Collaborating Centre, FIND works with more than 200 academic, industry, governmental, and civil society partners worldwide, on over 70 active projects that cross six priority disease areas.
German Center for Infection Research (DZIF): With 35 establishments at 7 sites across Germany, DZIF is specialized in translational infection research with the aim of developing new diagnostic, preventative and therapeutic methods for treating infectious diseases. DZIF actively engages in AMR research and promotes innovative product development through funding, project management and regulatory support.
Institute for Life Sciences Entrepreneurship (ILSE): A non-profit organization located at Kean University in Union, New Jersey, USA, ILSE provides incubator space and accelerator services to life science companies and is a science-driven research institute working in partnership with entrepreneurs and major academic, non-profit, and corporate organizations. ILSE’s American Type Culture Collection (ATCC) Center for Translational Microbiology focuses on research in microbiome, advanced microbial genomics, clinical multi-drug resistance, and bioinformatics.
Massachusetts Biotechnology Council (MassBio): MassBio is a not-for-profit organization that represents and provides services and support for Massachusetts companies in the life sciences sector. MassBio is based in Boston, a leading life sciences research hub.MassBio was the first biotechnology trade association formed in the US. Since its founding in 1985, MassBio has cultivated a preeminent life sciences knowledge base and talent network, and has renowned experience accelerating innovation through various programs. MassBio provides business support and mentoring services to CARB-X companies.
RTI International: RTI is an independent, non-profit institute based in North Carolina, USA, that provides research, development, and technical services to government and commercial clients worldwide. Our product development teams have expertise in toxicology, pharmacology, chemistry manufacturing and controls (CMC), and regulatory affairs. RTI’s extensive global network of consultants and contract research organization (CRO) partners enables the management of multiple product development programs. RTI staff have more than 100 years of combined pharmaceutical development experience and have filed 12 INDs in the past 4 years, including four for antimicrobial products. RTI currently supports a portfolio of products from discovery through Phase 3.
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis (CF) and to provide all people with the disease the opportunity to lead full lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care. In 2018, the CF Foundation committed more than $100 million to improve detection, diagnosis, prevention, and treatment as part of its Infection Research Initiative. The Foundation will be working with CARB-X to help identify companies interested in developing new treatments for CF-related infections.
The Defense Threat Reduction Agency (DTRA) offers CARB-X-funded product developers screening services to help them identify compounds with activity against bacteria that could potentially pose a biological threat. DTRA is the U.S. Department of Defense’s Combat Support Agency for Countering Weapons of Mass Destruction, Countering Improvised Threats, and Supporting an Effective and Reliable Nuclear Deterrent. It is a D0D combat support and defense agency tasked with combatting weapons of mass destruction. The screening services program was initiated and funded in a co-venture between DTRA and the U.S. Biomedical Advanced Research and Development Authority (BARDA), which launched and funds CARB-X.
Medicines for Malaria Venture (MMV) works with partners to catalyse the discovery, development and delivery of new effective and affordable antimalarial medicines. Over the past decade, MMV has brought forward 11 products with its partners, which have resulted in an estimate two million lives saved.
CARB-X’s collaboration with MMV involves running high throughput assays, screening antibacterial compounds belonging to CARB-X-funded product developers for their activity against the malarial parasite. MMV also offers partnership opportunities to see if any antimalarial compounds have activity against bacteria.